Platelet-dependent Thrombosis: a Placebo-controlled Trial of Antiplatelet Therapy (Clopidogrel)
This study has been completed.
Sponsor:
Newcastle-upon-Tyne Hospitals NHS Trust
Collaborators:
British Heart Foundation
University of Newcastle Upon-Tyne
Information provided by (Responsible Party):
Azfar G Zaman, Newcastle-upon-Tyne Hospitals NHS Trust
ClinicalTrials.gov Identifier:
NCT00728156
First received: August 1, 2008
Last updated: May 20, 2012
Last verified: May 2012
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Patients with diabetes are more likely to develop furring of their coronary arteries and present with angina and heart attacks. Furthermore, after such an event, they have poorer outcomes (higher rates of death) and survivors are more likely to have recurring symptoms. Using a novel "clotting chamber" the investigators have shown that patients with diabetes are more likely to develop blood clots. This study will look at the role of different blood thinning medications in patients with diabetes. If successful, the investigators will provide evidence to conduct large clinical studies to look at the role of additional blood thinning medication in reducing heart attacks and strokes in patients with diabetes.
| Condition | Intervention | Phase |
|---|---|---|
|
Type 2 Diabetes Mellitus Coronary Artery Disease |
Drug: clopidogrel Drug: placebo |
Phase 4 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor) Primary Purpose: Treatment |
| Official Title: | Assessment of Platelet-dependent Thrombosis by an ex Vivo Arterial Injury Model: a Placebo Controlled Trial of Clopidogrel as Antiplatelet Therapy in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease |
Resource links provided by NLM:
Further study details as provided by Newcastle-upon-Tyne Hospitals NHS Trust:
Primary Outcome Measures:
- To compare the effect of Clopidogrel in reduction of thrombogenicity in patients with T2DM and CAD with placebo [ Time Frame: seven days ] [ Designated as safety issue: No ]
Secondary Outcome Measures:
- To identify patients (in particular T2DM patients with CAD) resistant to oral antiplatelet therapy [ Time Frame: seven days ] [ Designated as safety issue: No ]
- To characterise features in T2DM patients responsible for increased thrombogenicity [ Time Frame: seven days ] [ Designated as safety issue: No ]
| Enrollment: | 90 |
| Study Start Date: | August 2009 |
| Study Completion Date: | April 2012 |
| Primary Completion Date: | December 2010 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Active Comparator: C
Patients assigned to clopidogrel in addition to their standard care.(all patients will be on aspirin)We aim to study the effect of clopidogrel as dual antiplatelet therapy in patients with established coronary artery disease and type 2 diabetes. Ninety patients with type 2 diabetes and stable coronary artery disease has been randomly treated with clopidogrel or placebo (45 each) for one week in addition to their standard care (including aspirin,75 mg once daily).
|
Drug: clopidogrel
75 milligrams, oral, clopidogrel, one tablet daily, for seven days after the baseline chamber study.
Other Names:
|
|
Placebo Comparator: P
Patients assigned to placebo in addition to their standard care.(all patients will be on aspirin).This is a single-centre randomised double-blind placebo-controlled parallel design study, comparing efficacy of clopidogrel versus placebo in patients with T2DM and coronary artery disease. Ninety patients have completed the study. All patients were on their routine medications as per standard practice. After informed consent, participants were randomised to receive either clopidogrel 75mg daily or placebo for 7 days.
|
Drug: placebo
Placebo: Hydroxy methyl cellulose, similar in weight to the active medication 75 mgs, oral tablets, once a day
|
Detailed Description:
The objective of this study is to compare the effect of Clopidogrel on platelet dependent thrombosis in patients with T2DM and CAD with placebo. The Badimon chamber, an ex vivo arterial injury model is used for this purpose. This model simulates the in vivo situation of high shear arterial wall damage and helps to quantify thrombus which is the sum endpoint of all haemostatic abnormalities seen in vitro.
Eligibility| Ages Eligible for Study: | 18 Years to 75 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
Patients with T2DM and CAS as defined below:
- Clinical definitions
- T2DM: Diagnosed according to the WHO criteria [53].
- CAD:Presence of any one of the following: Angina plus positive exercise tolerance test, enzyme and/or Q wave positive myocardial infarction, angiographic evidence ( >50% stenosis of one vessel), percutaneous or surgical coronary revascularisation.
- Aged between 18 and 75
- Provided written consent for participation in the trial prior to any study-specific procedures or requirements.
Exclusion Criteria:
- Contraindication to Clopidogrel
- Smoking (current smokers and patients who quit smoking less than six months)
- Malignancy(diagnosed or under investigation)
- Haematological disorders (Anaemia, malignancy, bleeding disorders)
- Women of child-bearing potential
- Use of corticosteroids/other antithrombotic agents(warfarin)
- Chronic liver disease (Cirrhosis, malignancy and patients with more than twice the upper limit of liver function tests)
- Unable to consent.
- Use of other investigational study drugs within 1 year prior to study entry
- Previous participation in this study
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00728156
Locations
| United Kingdom | |
| Newcastle Diabetes Centre, Newcastle General Hospital | |
| Newcastle upon Tyne, Tyne and Wear, United Kingdom, NE4 6BE | |
| Freeman Hospital | |
| Newcastle upon Tyne, Tyne and Wear, United Kingdom, NE77DN | |
Sponsors and Collaborators
Newcastle-upon-Tyne Hospitals NHS Trust
British Heart Foundation
University of Newcastle Upon-Tyne
Investigators
| Principal Investigator: | Azfar G Zaman, MD FRCP | Consultant cardiologist and Honoraray Lecturer |
More Information
Publications:
| Responsible Party: | Azfar G Zaman, Consultant Cardiologist and Reader, Newcastle-upon-Tyne Hospitals NHS Trust |
| ClinicalTrials.gov Identifier: | NCT00728156 History of Changes |
| Other Study ID Numbers: | 3639a, British Heart Foundation |
| Study First Received: | August 1, 2008 |
| Last Updated: | May 20, 2012 |
| Health Authority: | United Kingdom: Medicines and Healthcare Products Regulatory Agency United Kingdom: National Health Service United Kingdom: Research Ethics Committee |
Keywords provided by Newcastle-upon-Tyne Hospitals NHS Trust:
|
Type 2 Diabetes mellitus Coronary artery disease Platelet dependent thrombogenicity |
Aspirin Clopidogrel Badimon Chamber |
Additional relevant MeSH terms:
|
Coronary Artery Disease Myocardial Ischemia Coronary Disease Diabetes Mellitus Diabetes Mellitus, Type 2 Thrombosis Heart Diseases Cardiovascular Diseases Arteriosclerosis Arterial Occlusive Diseases Vascular Diseases Glucose Metabolism Disorders Metabolic Diseases Endocrine System Diseases Embolism and Thrombosis |
Clopidogrel Ticlopidine Platelet Aggregation Inhibitors Hematologic Agents Therapeutic Uses Pharmacologic Actions Purinergic P2Y Receptor Antagonists Purinergic P2 Receptor Antagonists Purinergic Antagonists Purinergic Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Fibrinolytic Agents Fibrin Modulating Agents |
ClinicalTrials.gov processed this record on May 23, 2013